TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06701812: Digoxin Medulloblastoma Study

Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 23 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$1,992,000

Rescue Site Savings

+$1,328,000

Unlock Full NCT06701812 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06701812 Rescue Dossier →